全文获取类型
收费全文 | 686篇 |
免费 | 37篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 47篇 |
妇产科学 | 20篇 |
基础医学 | 64篇 |
口腔科学 | 37篇 |
临床医学 | 90篇 |
内科学 | 203篇 |
皮肤病学 | 10篇 |
神经病学 | 23篇 |
特种医学 | 115篇 |
外科学 | 31篇 |
综合类 | 10篇 |
预防医学 | 22篇 |
眼科学 | 4篇 |
药学 | 62篇 |
1篇 | |
肿瘤学 | 28篇 |
出版年
2023年 | 5篇 |
2022年 | 5篇 |
2021年 | 5篇 |
2019年 | 4篇 |
2018年 | 10篇 |
2017年 | 9篇 |
2016年 | 13篇 |
2015年 | 15篇 |
2014年 | 20篇 |
2013年 | 25篇 |
2012年 | 16篇 |
2011年 | 17篇 |
2010年 | 22篇 |
2009年 | 26篇 |
2008年 | 14篇 |
2007年 | 49篇 |
2006年 | 20篇 |
2005年 | 15篇 |
2004年 | 11篇 |
2003年 | 9篇 |
2002年 | 12篇 |
2001年 | 4篇 |
2000年 | 8篇 |
1999年 | 11篇 |
1998年 | 44篇 |
1997年 | 52篇 |
1996年 | 54篇 |
1995年 | 44篇 |
1994年 | 30篇 |
1993年 | 30篇 |
1992年 | 2篇 |
1991年 | 11篇 |
1990年 | 7篇 |
1989年 | 14篇 |
1988年 | 24篇 |
1987年 | 19篇 |
1986年 | 14篇 |
1985年 | 14篇 |
1984年 | 6篇 |
1983年 | 8篇 |
1982年 | 9篇 |
1981年 | 8篇 |
1980年 | 11篇 |
1978年 | 4篇 |
1977年 | 8篇 |
1976年 | 2篇 |
1975年 | 4篇 |
1973年 | 1篇 |
1967年 | 1篇 |
1960年 | 1篇 |
排序方式: 共有769条查询结果,搜索用时 0 毫秒
21.
22.
Abruzzo LV; Schmidt K; Weiss LM; Jaffe ES; Medeiros LJ; Sander CA; Raffeld M 《Blood》1993,82(1):241-246
We describe a patient with angioimmunoblastic lymphadenopathy with dysproteinemia (AILD), who subsequently developed large-cell immunoblastic lymphoma of B-cell immunophenotype. At the time of the initial diagnosis, histologic examination of an inguinal lymph node showed typical features of AILD, and there was no evidence of a monoclonal B-cell population by immunohistochemical analysis. In situ hybridization and Southern blot analysis for Epstein-Barr virus (EBV) were negative. At autopsy 2 years later, the patient had widespread lymph node and organ involvement by large-cell immunoblastic lymphoma of B-cell immunophenotype. Southern blot analysis performed on DNA extracted from lymph nodes, liver, and spleen showed two patterns of Ig heavy chain and kappa light chain gene rearrangements. The T-cell receptor beta chain gene was in the germline configuration. Analysis with an EBV terminal repeat region probe showed two clonal populations that paralleled the Ig gene rearrangement studies. Double-labeling immunohistochemistry and in situ hybridization confirmed the presence of EBV within the neoplastic B cells. The data support the hypothesis that EBV was not etiologically related to AILD in this case, and that EBV proliferation may occur after the onset of the disease. Further, the data suggest that some B-cell lymphomas that arise in the setting of AILD resemble EBV-associated B-cell lymphomas that arise in other immunodeficiency states. 相似文献
23.
Fucoidin, but not yeast polyphosphomannan PPME, inhibits leukocyte rolling in venules of the rat mesentery 总被引:11,自引:3,他引:11
Leukocyte rolling in venules is inhibited by several sulfated polysaccharides, by antibodies to the leukocyte adhesion receptor L- selectin (LECAM-1), and by recombinant soluble L-selectin. The sulfated fucose polymer fucoidin and the polyphosphomannan PPME bind to L- selectin and inhibit L-selectin-mediated lymphocyte adhesion to lymph node high endothelial venules (LN-HEV). We investigated whether fucoidin and PPME also inhibit leukocyte rolling. Rolling leukocyte flux was determined by intravital microscopy in 47 venules (diameter 21 to 50 microns) of the rat mesentery with and without micro-infusion of each reagent through 8-microns glass micropipettes. Micro-infusion (1 mg/mL) or intravenous (IV) injection (25 mg/kg) of fucoidin, but not vehicle, reduced leukocyte rolling by greater than 90%. The half- effective concentration was approximately 2.5 micrograms/mL. Stroboscopic fluorescence video microscopy showed that fucoidin decreased the fraction of rolling leukocytes from 44% of all leukocytes passing the venules in control to less than 1%. PPME micro-infusion (1 mg/mL) or IV injection (14 mg/kg) did not reduce leukocyte rolling. Hence, leukocyte rolling differs from lymphocyte homing with respect to the effect of PPME. This may be related to fucoidin binding to L- selectin with greater affinity than PPME. Alternatively, inflamed venular endothelium may express a ligand for L-selectin different from that constitutively expressed on LN-HEV. 相似文献
24.
25.
26.
27.
28.
该文旨在介绍Beth Israel医疗中心采用大剂量术中放疗(HDR-IORT)治疗复发头颈癌的经验。对2001-2010年间头颈癌局部复发接受大剂量HDR-IORT的患者进行回顾分析。结果,76例患者的87个部位在肿瘤切除后接受了治疗。术后2年控制率为62%。平均总生存期为19个月,其中42%的患 相似文献
29.
María?Jesús?IzquierdoEmail author Mónica?Cavia Pilar?Mu?iz Angel?LM?de Francisco Manuel?Arias Javier?Santos Pedro?Abaigar 《BMC nephrology》2012,13(1):159
Background
Treatment with selective vitamin D receptor activators such as paricalcitol have been shown to exert an anti-inflammatory effect in patients on hemodialysis, in addition to their action on mineral metabolism and independently of parathyroid hormone (PTH) levels. The objective of this study was to evaluate the additional antioxidant capacity of paricalcitol in a clinical setting.Methods
The study included 19 patients with renal disease on hemodialysis, of whom peripheral blood was obtained for analysis at baseline and three months after starting intravenous paricalcitol treatment. The following oxidizing and inflammatory markers were quantified: malondialdehyde (MDA), nitrites and carbonyl groups, indoleamine 2,3-dioxygenase (IDO), tumor necrosis factor alfa (TNF-α), interleukin-6 (IL-6), interleukin-18 (IL-18) and C-reactive protein (CRP). Of the antioxidants and anti-inflammatory markers, superoxide dismutase (SOD), catalase, reduced glutathione (GSH), thioredoxin, and interleukin-10 (IL-10) levels were obtained.Results
Baseline levels of oxidation markers MDA, nitric oxide and protein carbonyl groups significantly decreased after three months on paricalcitol treatment, while levels of GSH, thioredoxin, catalase and SOD activity significantly increased. After paricalcitol treatment, levels of the inflammatory markers CRP, TNF-α, IL-6 and IL-18 were significantly reduced in serum and the level of anti-inflammatory cytokine IL-10 was increased.Conclusions
In renal patients undergoing hemodialysis, paricalcitol treatment significantly reduces oxidative stress and inflammation, two well known factors leading to cardiovascular damage.30.
Cardoso AA; Schultze JL; Boussiotis VA; Freeman GJ; Seamon MJ; Laszlo S; Billet A; Sallan SE; Gribben JG; Nadler LM 《Blood》1996,88(1):41-48
Even if neoplastic cells express tumor associated antigens they still may fail to function as antigen presenting cells (APC) if they lack expression of one or more molecules critical for the induction of productive immunity. These cellular defects can be repaired by physiologic activation, transfection, or fusion of tumor cells with professional APC. Although such defects can be repaired, antitumor specific T cells may still fail to respond in vivo if they may have been tolerized. Here, human pre-B cell acute lymphoblastic leukemia (pre-B ALL) was used as a model to determine if primary human tumor cells can function as alloantigen presenting cells (alloAPC) or alternatively whether they induce anergy. In the present report, we show that pre-B cell ALL express alloantigen and adhesion molecules but uniformly lack B7-1 (CD80) and only a subset express B7-2 (CD86). Pre-B ALL cells are inefficient or ineffective alloAPC and those cases that lack expression of B7-1 and B7-2 also induce alloantigen specific T- cell unresponsiveness. Under these circumstances, T-cell unresponsiveness could be prevented by physiologic activation of tumor cells via CD40, cross-linking CD28, or signaling through the common gamma chain of the interleukin-2 receptor on T cells. Taken together, these results suggest that pre-B ALL may be incapable of inducing clinically significant T-cell-mediated antileukemia responses. This defect may be not only due to their inability to function as APC, but also due to their potential to induce tolerance. Attempts to induce clinically significant antitumor immune responses may then require not only mechanisms to repair the antigen presenting capacity of the tumor cells, but also reversal of tolerance. 相似文献